Arvinas and Pfizer today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease…
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults. This approval of TNKase…
Could you share some significant milestones from your career? With over 25 years at the helm as Managing Director of Ami Polymer Pvt. Ltd. (APPL), me and my dynamic team have led the company to international prominence as a key player…
The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million patients in Europe. In 2022, Pierre Fabre…
GSK has today announced it has signed a 10-year energy deal with Sembcorp Industries Ltd, covering the electricity demand for all three of GSK’s global manufacturing sites in Singapore. This means that from 1 January 2025, all of GSK’s manufacturing…
Roche announced today that the World Health Organization (WHO) has awarded the cobas® HPV test prequalification designations for use on the cobas® 5800 system and for self-collected samples on the cobas® 5800, 6800 and 8800 systems. These new prequalification designations come…
As the nation’s premier middle school science competition, the annual 3M Young Scientist Challenge invites students in grades 5-8 to compete for an exclusive mentorship with a 3M scientist, a $25,000 grand prize, and the chance to earn the title…
AbbVie announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius’ lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1…
Gruppo Servier in Italia teams have launched a major information and awareness campaign on the importance of therapeutic adherence in treating chronic cardiovascular diseases. In partnership with SIPREC – Italian Society for Cardiovascular Prevention, the Affetti Desiderati campaign provides patients with access…
The 54th issue of Pharmaceutical Business Review International presents an exclusive interview with Ruşen Kalender, Chairman of the Board of World Medicine, one of Turkey’s prominent pharmaceutical manufacturers. Mr. Kalender shared insights into the company’s new investments supporting its ongoing…